Search research articles
Contact Us
Filters
Showing results (121-130 of 153) with videos related to
Page
of 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
Claus Garbe, Ulrike Keim, Stefan Suciu, et al.
Annals of Surgical Oncology
|
January 10, 2009
Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI)
Alessandro Testori, Gian Luca De Salvo, Maria Cristina Montesco, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
Vanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Cancer Investigation
|
February 4, 2014
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program
Paolo Antonio Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
The Lancet. Oncology
|
February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
Corneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2020
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection
Daniëlle Verver, A Rekkas, Claus Garbe, et al.
Human Molecular Genetics
|
October 4, 2021
Functional annotation and investigation of the 10q24.33 melanoma risk locus identifies a common variant that influences transcriptional regulation of OBFC1
Antonella Cardinale, Sueva Cantalupo, Vito Alessandro Lasorsa, et al.
The New England Journal of Medicine
|
June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Caroline Robert, Luc Thomas, Igor Bondarenko, et al.
Cancer
|
September 12, 2013
Pediatric melanoma: analysis of an international registry
Bruce J Averbook, Sandra J Lee, Keith A Delman, et al.
Page
of 16
Search research articles
Search
Showing results (121-130 of 153) with videos related to
Sort By:
Page
of 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 13, 2020
Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
Claus Garbe, Ulrike Keim, Stefan Suciu, et al.
Annals of Surgical Oncology
|
January 10, 2009
Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI)
Alessandro Testori, Gian Luca De Salvo, Maria Cristina Montesco, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
April 9, 2014
Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
Vanna Chiarion Sileni, Jacopo Pigozzo, Paolo Antonio Ascierto, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 11, 2019
Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial
Alexander M M Eggermont, Vanna Chiarion-Sileni, Jean-Jacques Grob, et al.
Cancer Investigation
|
February 4, 2014
Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian cohort of the ipilimumab expanded access program
Paolo Antonio Ascierto, Ester Simeone, Vanna Chiarion Sileni, et al.
The Lancet. Oncology
|
February 7, 2017
Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial
Corneel Coens, Stefan Suciu, Vanna Chiarion-Sileni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2020
The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-positive melanoma without the need for completion lymph node dissection
Daniëlle Verver, A Rekkas, Claus Garbe, et al.
Human Molecular Genetics
|
October 4, 2021
Functional annotation and investigation of the 10q24.33 melanoma risk locus identifies a common variant that influences transcriptional regulation of OBFC1
Antonella Cardinale, Sueva Cantalupo, Vito Alessandro Lasorsa, et al.
The New England Journal of Medicine
|
June 7, 2011
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
Caroline Robert, Luc Thomas, Igor Bondarenko, et al.
Cancer
|
September 12, 2013
Pediatric melanoma: analysis of an international registry
Bruce J Averbook, Sandra J Lee, Keith A Delman, et al.
Page
of 16